Vaccination of pregnant ponies against equine rhinopneumonitis.
Bovine herpesvirus 1247 (one dose) was given subcutaneously to five pregnant pony mares between 227 and 319 days of their gestations. There were no adverse clinical reactions, and the virus was not recovered from nasal swabs collected during a 2-week period after vaccination. Four ponies foaled full-term, live, healthy foals. The foal of the fifth mare (No. 1) was found dead, but on the basis of the pathologic and virologic examinations, the virus was not considered to be the cause of the death. At 3 weeks after vaccination, the pregnant pony mares had a 13- to 250-fold increase in serum antibody titer to equine herpesvirus-1. A virulent-virus challenge exposure of all pony mares at 208 days after vaccination resulted in antibody titers greater than those just before this exposure. Virus was recovered from nasal swabs from vaccinated mares only on postexposure day 1, whereas the one control (nonvaccinated) pony shed virus for at least 3 days after challenge exposure. The immunogenic and the nonabortifacient characteristics of the herpesvirus 1247 in pregnant pony mares indicate that it may be useful to vaccinate horses against equine herpesvirus-1.
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology; D000914:Antibodies, Viral / Q000032:analysis; D005260:Female; D006564:Herpesviridae / Q000276:immunology; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D004861:Herpesvirus 1, Equid / Q000276:immunology; D006734:Horse Diseases / Q000517:prevention & control*; D006736:Horses / Q000276:immunology*; D007112:Immunity, Maternally-Acquired; D011247:Pregnancy; D014611:Vaccination / Q000662:veterinary*
D000914:Antibodies, Viral